Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled time : 14:20 save search
Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
Published: 2023-07-25 (Crawled : 14:20) - globenewswire.com
NYMX | $0.2 -19.68% -23.88% 930K
|
Health Technology
| Email alert
Add to watchlist
cancer treatment trial results
Arkuda Therapeutics to Present Update on ARKD-104, its First-in-Class Oral Development Candidate for the Treatment of Frontotemporal Dementia
Published: 2023-07-18 (Crawled : 14:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.04%
H: 1.43%
C: 0.95%
arkd-104 candidate update treatment dementia therapeutics
FDA Approves Fabry Disease Treatment from Chiesi, Protalix
Published: 2023-05-10 (Crawled : 14:20) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.75%
H: 0.0%
C: 0.0%
fda disease treatment
DUPIXENT (dupilumab injection) is now approved in Canada for the treatment of adult and adolescent patients (12+) with Eosinophilic Esophagitis
Published: 2023-05-04 (Crawled : 14:20) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.56%
H: 0.0%
C: 0.0%
approved dupixent treatment canada
Libtayo (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer
Published: 2023-05-01 (Crawled : 14:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 4.08%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
lung approved cancer cell treatment libtayo canada
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Published: 2022-03-21 (Crawled : 14:20) - globenewswire.com
VRDN | $15.17 0.6% 0.59% 580K
|
Health Care and Social Assistan...
|
| O: 0.75%
H: 6.59%
C: 1.34%
vrdn-002 disease antibody treatment thyroid eye trial therapeutics
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
Published: 2023-04-25 (Crawled : 14:20) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: -8.67%
H: 9.49%
C: -30.29%
inb-400 fda drug treatment designation glioblastoma
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
Published: 2023-04-11 (Crawled : 14:20) - ir.auriniapharma.com
AUPH | $4.81 -2.04% -2.08% 2.1M
|
Health Technology
|
| O: 1.01%
H: 11.13%
C: 9.73%
lupkynis patent lupus treatment pharmaceuticals
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-04-06 (Crawled : 14:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.79%
H: 0.86%
C: 0.6%
CNSP | $0.1975 -3.38% -3.49% 130K
|
Health Technology
|
| O: 53.58%
H: 6.02%
C: -43.6%
approval berubicin treatment pharmaceuticals global trial
CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
Published: 2023-04-03 (Crawled : 14:20) - biospace.com/
CRVS | $1.43 5.15% 4.9% 140K
|
Health Technology
|
| O: -3.3%
H: 13.64%
C: 13.08%
cpi-818 cell treatment immunotherapy potential
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
Published: 2023-03-09 (Crawled : 14:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -2.68%
H: 5.52%
C: 3.54%
CNSP | $0.1975 -3.38% -3.49% 130K
|
Health Technology
|
| O: -2.72%
H: 4.3%
C: -5.59%
treatment ongoing pharmaceuticals global trial berubicin momentum switzerland
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
Published: 2023-02-15 (Crawled : 14:20) - biospace.com/
VBIV | $0.6001 -1.46% -1.48% 180K
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: -4.19%
vbi-2601 treatment hepatitis brii-835 presentation chronic hepatitis b
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
Published: 2023-02-09 (Crawled : 14:20) - prnewswire.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: 1.32%
H: 12.34%
C: 11.69%
treatment neurodegenerative
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
Published: 2023-02-08 (Crawled : 14:20) - globenewswire.com
SAVA | $21.18 -0.42% -0.42% 970K
|
Health Technology
|
| O: 0.0%
H: 5.42%
C: -1.24%
treatment sciences disease alzheimer’s update
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
Published: 2023-02-06 (Crawled : 14:20) - ir.pulmatrix.com
PULM | $1.95 -6.7% -7.18% 31K
|
Health Technology
|
| O: 1.82%
H: 3.44%
C: 1.42%
pur1900 treatment study phase 2b
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2023-02-02 (Crawled : 14:20) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -2.3%
H: 2.11%
C: 1.78%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.31%
H: 0.05%
C: -0.33%
ARTL | $1.29 -1.9% -1.94% 14K
|
Health Technology
|
| O: -1.27%
H: 1.67%
C: -0.96%
art27 treatment cares trial art27.13 phase 2b
Power REIT Announces 2022 Dividend Income Tax Treatment
Published: 2023-01-30 (Crawled : 14:20) - globenewswire.com
PW | $0.52 1.96% -1.92% 6.6K
|
Finance
|
| O: -2.71%
H: 7.89%
C: -0.23%
treatment
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
GH M | $16.68 1.77% 1.74% 1.6M
|
Health Services
|
| O: -1.0%
H: 0.93%
C: -0.03%
treatment blood test health trial trust cancer
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
BICX | $1.47 201.91% 200
|
Health Care and Social Assistan...
|
| O: 3.25%
H: 0.0%
C: 0.0%
bicx104 treatment opioid trial study
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: -1.51%
H: 6.12%
C: 2.55%
treatment designation drug granted therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.